Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

Natural killer cells aren't just mindless defenders — a special type, adaptive NK cells, remember their enemies and come back ...

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the ...

More information: Seok Jin Kim et al, Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma, Blood Journal (2025). DOI: 10.1182/blood.

which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK ...